EUROTOX 2015 Workshop W 13 Risk assessment of endocrine disruptors: is there data in support to deviate from the traditional approach relying on potency?
CPxxxxxxx-1 Long Acting Methylphenidate for Cancer Related Fatigue: NCCTG trial N05C7 DL Barton AR Moraska A Sood S Dakhil JA Sloan K Rowland JD Bearden.
Cutaneous Manifestations of Internal Disease Adam O. Goldstein, MD, MPH Associate Professor Family Medicine University of North Carolina at Chapel Hill.
Daniel I. Sessler Department of O UTCOMES R ESEARCH Cleveland Clinic on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
Daniel I. Sessler Department of O UTCOMES R ESEARCH Cleveland Clinic
CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS
ASCO 2006 Update Novel Therapeutics in Prevention and Treatment for Breast Cancer
Unit 9 Diagnosis and Treatment of Paediatric TB: B Family Case
